Sell NVO by May 25, 2026.

Novo announced yesterday they're cutting Wegovy list prices 50% and Ozempic prices up to 40%. This came one day after CagriSema — their next-gen obesity drug that was supposed to close the gap on Lilly's Zepbound — missed the primary endpoint in a head-to-head trial. NVO is down 60% from its 2024 peak. Copenhagen shares at their lowest since June 2021. **I went back and found every major case of a company cutting flagship product prices 30%+ under pressure and …